Haematopoietic stem cell transplantation for refractory Crohn's disease has the potential to halt therapy-resistant inflammation. Hawkey et al. argue that HSCT does not offer sustained benefit based upon their recent study; however, their study was designed using suboptimal end points and patients were not offered post-transplantation Crohn's disease medication.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn’s disease
BMC Research Notes Open Access 06 October 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hawkey, C. J. et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 314, 2524–2534 (2015).
Duijvestein, M., van den Brink, G. R. & Hommes, D. W. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J. Crohns Colitis 2, 99–106 (2008).
Burt, R. K. et al. Risks of immune system treatments. Science 328, 825–826 (2010).
Muraro, P. A. et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201, 805–816 (2005).
Zhang, L. et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-β-producing CD8+ Treg cells are associated with immunological remission of lupus. J. Immunol. 183, 6346–6358 (2009).
Burt, R. K. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 116, 6123–6132 (2010).
D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).
Wolters, F. L. et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 55, 510–518 (2006).
Lichtenstein, G. R. et al. Serious infections and mortality in associations with therapies for Crohn's disease: TREAT registry. Clin. Gastroent. Hepatol. 4, 621–630 (2006).
Farge, D. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group For Blood And Marrow Transplantation Working Party On Autoimmune Diseases. Haematologica 95, 284–292 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hommes, D., Lacey, P. HSCT for Crohn's disease: work in progress or a bridge too far?. Nat Rev Gastroenterol Hepatol 13, 128–130 (2016). https://doi.org/10.1038/nrgastro.2016.22
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2016.22